At the same time, there is a significant need for new therapies that not only alleviate symptoms but also slow down or modify disease progression. This is a key objective of the research conducted at Neuro-SysMed.
We are currently conducting several clinical studies on Parkinson’s disease, investigating new treatment possibilities in a safe and systematic manner. Through these studies, we aim to provide patients with access to research-based treatments and contribute to improving care for future generations of patients.
Contact
For more information on the studies or to join a study, please contact: neurosysmedstudier@helse-bergen.no
Current clinical trials and platforms in the PD group in Bergen
- The NADAPT Study: A Phase II Randomised Controlled Trial of NAD Replenishment Therapy for Atypical Parkinsonism
- SLEIPNIR: a Clinical Trial Accelerator and Derisking Platform for Parkinson’s Disease
- HYDRA: An Adaptive Multiarm Multistage Clinical Trial for Parkinson’s Disease
- NADream: A Randomised Double-blind Trial to Explore the Effects of NAD Augmentation Therapy on Sleep Physiology
- The NADage Study: A Randomised Double-blind Trial of NAD Replenishment Therapy on Aging
- NOR-RBD: A Longitudinal Cohort and Clinical Trial Platform for Prodromal α-Synucleinopathies
- The STRAT-PARK Study: A Prospective Multimodal Cohort Study to Stratify Parkinson’s Disease and Other Parkinsonisms
- D-SPARK: A Randomized Double Blind Clinical Trial of D-Serine for
Modifying Parkinson’s Disease Progression
Completed clinical trials from the PD group in Bergen
- NAD-PARK: Nikotinamide therapy for Parkinson's disease
- Park-Ome
- Nedsatt mitokondrie-homeostase som ein cellemodell for nevrodegenerasjon
- The NR-SAFE Study: a Safety Tolerability Study of High-dose Oral NR in Parkinson’s Disease
- N-DOSE study: Nikotinamide riboside therapy for Parkinson's disease
- The NADbrain Study: A Pharmacokinetic Study of NAD Replenishment in Human Blood and Brain
- The NOPARK Study: A Phase III Randomised Controlled Trial of Nicotinamide Riboside in Early Parkinson’s Disease
- The NOPARK Extension Study: An Open Label Trial of Long-Term Treatment with Nicotinamide Riboside (NR) in Parkinson’s Disease
- ActiveAgeing, DIGI.PARK: Digital Phenotyping in people with Parkinson’s Disease
- The REASON study, led by Biogen: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease.
Last updated 7/3/2026